Paclitaxel-albumin

DRUG13 trials

Sponsors

Zhejiang Provincial People's Hospital, Sun Yat-sen University, Xuefei.Wang, Zhejiang Cancer Hospital, Guangdong Provincial People's Hospital

Conditions

Breast CancerCervical CancerEsophageal CancerEsophageal Squamous Cell CarcinomaEsophagus CancerExtrafascial HysterectomyFirst-line Advanced NSCLC PatientsFludzoparib" and Anti-angiogenic

Phase 2

Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer

TerminatedNCT03585062

Zhejiang Provincial People's HospitalNeoadjuvant Chemotherapy, Pancreatic Cancer

Start: 2017-11-20End: 2019-07-01Updated: 2021-01-08

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Active, not recruitingNCT04172259

Sun Yat-sen UniversityBreast Cancer, Neoadjuvant Chemotherapy

Start: 2019-01-10End: 2026-09-30Target: 156Updated: 2023-10-16

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Active, not recruitingNCT04844385

Sun Yat-sen UniversityEsophageal Squamous Cell Carcinoma

Start: 2021-02-20End: 2024-12-20Updated: 2024-02-09

HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction

Not yet recruitingNCT05095467

Xuefei.WangPeritoneal Metastases, Stomach Neoplasms

Start: 2021-10-31End: 2026-10-31Target: 157Updated: 2021-10-27

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

Zhejiang Cancer HospitalStage IV Esophagus Squamous Cell Carcinoma

Start: 2022-04-15End: 2025-04-15Target: 80Updated: 2022-04-11

Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients

Guangdong Provincial People's HospitalEsophageal Squamous Cell Carcinoma, Immunotherapy, Patient-reported Outcomes

Start: 2022-11-30End: 2025-09-30Target: 50Updated: 2022-11-28

Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC

CompletedNCT05807542

Shanghai Zhongshan HospitalEsophagus Cancer

Start: 2022-03-01End: 2024-04-30Updated: 2024-05-16

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

RecruitingNCT06100497

Beijing Tongren HospitalHead and Neck Squamous Cell Carcinoma

Start: 2023-10-01End: 2028-10-31Target: 100Updated: 2024-08-09

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

RecruitingNCT06288360

Tongji HospitalCervical Cancer, Locally Advanced Cervical Cancer, Neoadjuvant Chemoimmunotherapy +1

Start: 2024-09-12End: 2030-12-12Target: 40Updated: 2025-03-20

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

RecruitingNCT06289751

Tongji HospitalCervical Cancer, Extrafascial Hysterectomy, Neoadjuvant Chemoimmunotherapy +1

Start: 2024-09-03End: 2031-01-01Target: 50Updated: 2024-09-19

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

RecruitingNCT06412471

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.First-line Advanced NSCLC Patients

Start: 2024-07-26End: 2025-08-31Target: 235Updated: 2024-07-30

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

RecruitingNCT06718205

The First Affiliated Hospital of Zhengzhou UniversityEsophageal Cancer

Start: 2023-03-08End: 2025-09-30Target: 112Updated: 2024-12-05

Phase 3

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

RecruitingNCT06255392

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityFludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer

Start: 2024-06-12End: 2031-03-31Target: 200Updated: 2025-08-15

Related Papers

Neoadjuvant chemotherapy plus cadonilimab followed by extra-fascial hysterectomy for International Federation of Gynecology and Obstetrics stage IB2 cervical cancer: a prospective, multi-center, single-arm, phase 2 trial.

2026-01-05

Decision analysis of PD-1 inhibitor combined with chemotherapy in neoadjuvant therapy of resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC).

Journal of Clinical Oncology2025-05-28

Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial.

2025-04-054 citations

Electronic patient-reported outcome-based surveillance system to evaluate safety and efficacy of preoperative immunochemotherapy with or without short-term chemoradiation in patients with esophageal squamous cell carcinoma (ePRO-PICCRT): protocol for a prospective, single-arm, phase II study

Journal of Thoracic Disease2024-07-011 citations

Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS).

Journal of Clinical Oncology2024-06-011 citations

Neoadjuvant toripalimab plus chemotherapy followed by concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (GASTO 1071).

Journal of Clinical Oncology2024-06-011 citations

Baseline heterogeneity of myeloid and stroma cells to predict pCR, baseline lymph node (LN) metastasis, and 1-year EFS in locally advanced ESCC with neoadjuvant immunotherapy: Final results from a single-arm, phase II clinical trial (SEEK-01).

Journal of Clinical Oncology2024-06-01